Lung cancer – Erlotinib

Reports looking at Erlotinib for the treatment of non-small cell lung cancer and the risk and costs of febrile neutropenia in patients with non-small cell lung cancer treated with docetaxel.

Off

NICE appraisal

TA162 Erlotinib for the treatment of non-small cell lung cancer (PDF, 29KB) (November 2008)

DSU reports

Erlotinib for the treatment of non-small cell lung cancer: Report from the Decision Support Unit in response to additional data submitted by Roche (PDF, 29KB) (January 2008)

The risk and costs of febrile neutropenia in patients with non-small cell lung cancer treated with docetaxel (PDF, 158KB) (December 2007)

Related publications

A Wailoo, A Sutton, A Morgan, 2009 British Journal of Cancer Vol 100: 436-441

Related information

Appraisal specific projects

A global reputation

91Ö±²¥ is a world top-100 research university with a global reputation for excellence. We're a member of the Russell Group: one of the 24 leading UK universities for research and teaching.

91Ö±²¥ the University